Video

Dr. George on the Importance of Understanding Mutations in Prostate Cancer

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

Daniel J. George, MD, professor of medicine, professor in surgery, Duke Cancer Institute, discusses the importance of understanding mutations in prostate cancer.

The treatment landscape for patients with prostate cancer continues to change due to multiple factors, Goerge said. These changes can be attributed to the recognition that it’s not a monolithic disease, George adds. Prostate cancer is comprised of different subsets which can be defined by the genetic makeup of these cancers, George explains.

Moreover, the genetic makeup of prostate cancer in addition to active mutations that are associated with the disease can help define a patient’s disease, George continues. The phenotype, patterns of the disease, and molecular uptake on PET imaging can all help clinicians understand which tumors are responsive to specific therapies, George concludes.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD